EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line treatment for patients with locally advanced or metastatic EGFR mutation non-small cell lung cancer (NSCLC) (Hanna et al., 2017; Planchard et al., 2018).